Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Patients could be made fundholders

The European Society of Cardiology has released new guidelines on heart failure that go beyond NICE in urging GPs to use triple drug therapy in all patients.

The society said the combination of ACE inhibitor and betablocker should no longer be considered sufficient.

Professor John Cleland, member of the guidelines taskforce, told Pulse: 'NICE does talk about ARBs, but not about the three together.

'The ESC guidelines suggest just using ACE inhibitors and betablockers is no longer optimal. Most patients with heart failure, certainly due to left ventricular systolic dysfunction, should be on a combination of ACE inhibitor, betablocker and an ARB or aldosterone receptor antagonist.'

The new guidelines, published in the European Heart Journal this week and discussed at the conference, also put further emphasis on the use of natriuretic peptides and promote the use of cardiac resynchronisation devices.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say